1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Patología Molecular del Cáncer

Patología Molecular del Cáncer

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Quindós-Varela M, Soto de Prado-Otero D, Gallego A, García Y, Guerra E, Estévez-García P, Barretina-Ginesta MP, Borraz P, González-Martín A, Rubio MJ.

    Management and Clinical Outcomes of Patients with Advanced Ovarian Cancer in Routine Clinical Practice in Spain: The OVOC Study

    Oncology and Therapy . 13(3): 631-648.

    [doi:10.1007/s40487-025-00347-1]

  • Massari F, Mollica V, Kopp RM, Grande E, Fiala O, Kanesvaran R, Li H, Schieber TJ, Juan Fita MJ, Poprach A, Lolli C, Bourlon MT, de Liaño AG, Grillone F, Sunela K, Rizzo A, Ghosn M, Cerbone L, Taha T, Ürün Y, Molina-Cerrillo J, Alonso-Gordoa T, Lenci E, Martin IO, Abu-Sini H, Rescigno P, Bhuva D, Fay AP, Conteduca V, Yildirim A, Rosellini M, Akova U, Tassinari E, Bölek H, Soares A, Marques Monteiro FS, Buti S, Bilen MA, Santoni M.

    Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study

    European Urology Focus . 11(5): 736-746. Nº de citas: 8

    [doi:10.1016/j.euf.2025.05.020]

  • López-Miranda E, Pérez-García JM, Gión M, Ribelles N, Cortez-Castedo P, Alonso-Romero JL, García MM, González-Santiago S, Bermejo B, Morales S, Carañana V, Garrigós L, Fernández-Pinto M, García-Vicente S, Garcia-Sanz A, Mena-Molina A, Boix O, Alcalá-López D, Llombart-Cussac A, Cortés J.

    Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial

    BREAST CANCER RESEARCH . 27(1): 141-141. Nº de citas: 1

    [doi:10.1186/s13058-025-02089-4]

  • Kime A, Bataillon G, Treilleux I, Callens C, Selle F, Heitz F, Cinieri S, González-Martin A, Schauer C, Lindahl G, Parma G, Vergote I, Matsumoto T, Blonz C, Canzler U, Mosconi AM, Guerra Alía EM, Pujade-Lauraine E, Genestie C, Ray-Coquard I, Just PA.

    Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma? Lessons From the PAOLA-1/ENGOT-ov25 Trial, a GINECO Study

    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE . 149(8): 741-750. Nº de citas: 4

    [doi:10.5858/arpa.2024-0081-OA]

  • Gion M, Blancas I, Cortez-Castedo P, Cortés-Salgado A, Marmé F, Blanch S, Morales S, Díaz N, Calvo-Plaza I, Recalde S, Martínez-Bueno A, Ruiz-Borrego M, Llabrés E, Taberner MT, de Laurentiis M, García-Vicente S, Guerrero JA, Boix O, Rodríguez-Morató J, Sampayo-Cordero M, Antonarelli G, Pérez-García JM, Cortés J, Llombart-Cussac A.

    Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial

    NATURE MEDICINE . 31(8): 2746-2754. Nº de citas: 26

    [doi:10.1038/s41591-025-03734-3]

  • Zapatero A, Alonso-Gordoa T, Rodríguez Antolín A, Couñago F, Sanmamed N, Domínguez Esteban M, López Valcárcel M, Manneh R, Borque-Fernando Á, Sala González N, Maroto P.

    Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach.

    Oncology Reviews . 19: 1599292-1599292. Nº de citas: 4

    [doi:10.3389/or.2025.1599292]

  • Bourlon MT, Galli L, Grande E, Park SH, Melichar B, Schieber TJ, Juan-Fita MJ, Ürün Y, Molina-Cerrillo J, Alonso-Gordoa T, De Giorgi U, Kucharz J, Pérez Calabuig E, Conteduca V, Taha T, Rescigno P, Abu-Sini H, Spinelli GP, Manneh Kopp R, Salfi A, Bhuva D, Valdez-Sandoval P, Mendez-Bribiesca S, Fiala O, Buti S, Marques Monteiro FS, Bamias A, Ghosn M, Massari F, Ansari J, Santoni M.

    Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study

    Frontiers in Oncology . 15: 1605282-1605282. Nº de citas: 4

    [doi:10.3389/fonc.2025.1605282]

  • Manneh R, Molina-Cerrillo J, de Velasco G, Ibatá L, Martínez S, Ruiz-Granados Á, Alonso-Gordoa T.

    PARP Inhibitors for Metastatic CRPC: More Answers than Questions, a Systematic Review and Meta-Analysis

    Pharmaceuticals . 18(7): . Nº de citas: 1

    [doi:10.3390/ph18071015]

  • Gorospe L, Saavedra-Serrano C, Martínez-Jáñez N.

    Eribulin-induced pulmonary toxicity mimicking metastatic lung disease.

    MEDICINA CLINICA . 165(1): 106993-106993.

    [doi:10.1016/j.medcli.2025.106993]

  • Loibl S, Martin M, Bonnefoi H, Untch M, Kim SB, Bear HD, García-Sáenz JA, Melé Olivé M, Mc Carthy N, Gelmon K, Kelly CM, Im SA, Reimer T, Martinez-Janez M, Zhang Z, Toi M, Provencher L, Rugo HS, Gnant M, Makris A, Antón Torres A, Hirmas N, Holtschmidt J, Nekljudova V, Marmé F.

    Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.

    ANNALS OF ONCOLOGY . 36(7): 832-837. Nº de citas: 17

    [doi:10.1016/j.annonc.2025.03.010]

  • Pérez-García JM, Gion M, Ruiz-Borrego M, Blancas I, López-Miranda E, Blanch S, Recalde S, Rendo CR, González X, Ancizar N, Morales S, Cortez P, Piwowarska Z, Shimizu E, Guerrero JA, Sampayo-Cordero M, Martínez-Bueno A, Cortés J, Llombart-Cussac A.

    Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial

    EClinicalMedicine . 85: 103309-103309. Nº de citas: 15

    [doi:10.1016/j.eclinm.2025.103309]

  • Téllez L, Toledano M, Álvarez M, Garrido-Lestache E, Garrido E, Guerrero A, Donate J, Canova L, Torres M, Perna C, Del Cerro MJ, Albillos A.

    Distinctive hemodynamic phenotype in Fontan-type circulation patients with distal esophageal varices

    HEPATOLOGY . : . Nº de citas: 3

    [doi:10.1097/HEP.0000000000001472]

  • Porta C, Massari F, Taha T, Grande E, Bourlon MT, Kanesvaran R, Basso U, Molina-Cerrillo J, Alonso-Gordoa T, Myint ZW, Fornarini G, Buttner T, Park SH, Ürün Y, De Giorgi U, Pichler R, Rescigno P, Buchler T, Studentova H, Melichar B, Ansari J, Mollica V, Kucharz J, Rizzo M, Rizzo A, Kopp RM, Buti S, Monteiro FSM, Soares A, Bamias A, Santoni M.

    Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON-1 study

    CANCER IMMUNOLOGY IMMUNOTHERAPY . 74(7): 196-196. Nº de citas: 10

    [doi:10.1007/s00262-025-04019-x]

  • Alonso-Gordoa T, Anguera G, Domínguez-Esteban M, Reig Ò, Martínez-Barros H, Molina-Cerrillo J, Cruz P, Maroto P.

    Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies.

    CANCER TREATMENT REVIEWS . 136: 102925-102925. Nº de citas: 3

    [doi:10.1016/j.ctrv.2025.102925]

  • Herranz-Montoya I, Angulo-Aguado M, Perna C, Zagorac S, García-Jimeno L, Park S, Djouder N.

    p53 protein degradation redefines the initiation mechanisms and drives transitional mutations in colorectal cancer

    Nature Communications . 16(1): 3934-3934. Nº de citas: 6

    [doi:10.1038/s41467-025-59282-4]

  • Capdevila J, Pubul V, Anido U, Walter T, Molina-Cerrillo J, Alonso-Gordoa T, Garcia-Carbonero R, San-Roman-Gil M, Llana B, Jimenez-Fonseca P, Benavent Viñuales M, Ansquer C, Baudin E, Lepage C, Del Olmo-García M, Ruffinelli JC, Beron A, Haissaguerre M, Deshayes E, Taïeb D, Baldari S, Sansovini M, Cingarlini S, Filice A, Panzuto F, Álvarez-Álvarez R, Lousberg L, Aboubakar Nana F, Hernando J, García-Álvarez A, García-Burillo A, Villacampa G, Vandamme T, Fazio N, Durand A.

    A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)

    BMC CANCER . 25(1): 613-613. Nº de citas: 9

    [doi:10.1186/s12885-025-13941-3]

  • Borque-Fernando Á, Alonso-Gordoa T, Juan-Fita MJ, Lopez Campos F, Pérez-Fentes DA, Vilaseca A, Agut CM, Usán P, Rey PM.

    Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC

    Future Oncology . 21(8): 991-1003. Nº de citas: 3

    [doi:10.1080/14796694.2025.2468569]

  • Cortés-Salgado A, Moreno-Moreno E, Carretero-Barrio I, Caniego-Casas T, Cristóbal E, Del Campo-Albendea L, Guerra E, Alía V, de Aguado PP, Corraliza V, Palacios J, Pérez-Mies B.

    HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study

    Gynecologic Oncology . 194: 33-40. Nº de citas: 9

    [doi:10.1016/j.ygyno.2025.02.005]